# Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults

> **NCT07147400** · PHASE2 · RECRUITING · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 1200 (estimated)

## Conditions studied

- Prevention of Malaria Transmission and Clinical Malaria

## Interventions

- **BIOLOGICAL:** 10µg of R21 with 50µg Matrix-M1
- **BIOLOGICAL:** 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation
- **BIOLOGICAL:** RABIVAX-S
- **BIOLOGICAL:** Conjugated Pfs230D1 Vaccine (Pfs230D1-CRM197) For Bedside Mixing
- **BIOLOGICAL:** R21 Malaria Vaccine (Recombinant) For Bedside Mixing
- **BIOLOGICAL:** MATRIX-M1 (Adjuvant) For Bedside Mixing

## Key facts

- **NCT ID:** NCT07147400
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147400, "Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT07147400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*